Western Blotting (WB), ELISA, Immunofluorescence (IF), Immunocytochemistry (ICC)
Aufreinigung
VPS53 Antibody is affinity chromatography purified via peptide column.
Immunogen
VPS53 antibody was raised against a 18 amino acid synthetic peptide from near the carboxy terminus of human VPS53. The immunogen is located within the last 50 amino acids of VPS53.
VPS53
Reaktivität: Human
Wirt: Kaninchen
Polyclonal
Alexa Fluor 680
Applikationshinweise
VPS53 antibody can be used for detection of VPS53 by Western blot at 0.5 - 1 μ,g/mL. Antibody can also be used for immunocytochemistry starting at 5 μ,g/mL. For immunofluorescence start at 2.5 μ,g/mL.
Antibody validated: Western Blot in human samples, Immunocytochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1 mg/mL
Buffer
VPS53 Antibody is supplied in PBS containing 0.02 % sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
-20 °C,4 °C
Informationen zur Lagerung
VPS53 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Target
VPS53
(Vacuolar Protein Sorting 53 Homolog (VPS53))
VPS53 Antibody: The sorting of acid hydrolases to lysosomes rely on mannose 6-phosphate receptors that cycle between the trans-Golgi network (TGN) and endosomes. The maintenance of this cycle requires the function of the mammalian Golgi-associated retrograde protein (GARP) complex which is composed of three subunits: VPS52, VPS53, and VPS54. Depletion of any of these three proteins, such as by RNAi, impairs the retrograde transport of multiple TGN proteins. VPS53 was identified as an HIV dependency factor (HDF) and plays a role in viral entry to the cell, suggesting that VPS53 may be an important drug target in HIV treatment. At least five isoforms of VPS53 are known to exist.